Generation of monoclonal antibodies against human prion proteins in PrP0/0 mice

被引:162
作者
Krasemann, S
Groschup, MH
Harmeyer, S
Hunsmann, G
Bodemer, W
机构
[1] GERMAN PRIMATE CTR,DEPT VIROL & IMMUNOL,DPZ,D-37077 GOTTINGEN,GERMANY
[2] FED RES CTR VIRUS DIS ANIM,D-7400 TUBINGEN,GERMANY
关键词
D O I
10.1007/BF03401656
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Prion diseases belong to a group of neurodegenerative disorders affecting humans and animals. The human diseases include kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome (GSS), and fatal familial insomnia (FFI). The pathogenic mechanisms of the prion diseases are not yet understood. Monoclonal antibodies provide valuable tools in the diagnosis, as well as in the basic research, of several diseases; however, monospecific antisera or monoclonal antibodies (mAbs) against human prion proteins were, until now, not available. Materials and Methods: We have developed an immunization protocol based on nucleic acid injection into nontolerant PrP0/0 mice. DNA or RNA coding for different human prion proteins including the mutated sequences associated with CJD, GSS, and FFI were injected into muscle tissue. Mice were primarily inoculated with DNA plasmids encoding the prion protein (PRNP) gene and boosted either with DNA, RNA, or recombinant Semliki Forest Virus particles expressing PRNP. Hybridomas were then prepared. Results: Different mAbs against human prion proteins were obtained, and their binding behavior was analysed by peptide enzyme-linked immunosorbent assay, Western blot, nonimmunofluorescence, and immunoprecipitation. Their cross-reactivity with prion protein from other species was also determined. Our mAbs are directed against four different linear epitopes and may also recognize discontinuous regions of the native prion protein. Conclusions: These antibodies should allow us to address questions concerning the nature of the prion protein as well as the initiation and progression of prion diseases. Moreover, these mAbs can now be used for the diagnosis of prion diseases of humans and animals.
引用
收藏
页码:725 / 734
页数:10
相关论文
共 28 条
[1]  
BARRY RA, 1988, J IMMUNOL, V140, P1188
[2]   SEMLIKI FOREST VIRUS EXPRESSION SYSTEM - PRODUCTION OF CONDITIONALLY INFECTIOUS RECOMBINANT PARTICLES [J].
BERGLUND, P ;
SJOBERG, M ;
GAROFF, H ;
ATKINS, GJ ;
SHEAHAN, BJ ;
LILJESTROM, P .
BIO-TECHNOLOGY, 1993, 11 (08) :916-920
[3]   IATROGENIC CREUTZFELDT-JAKOB-DISEASE - AN EXAMPLE OF THE INTERPLAY BETWEEN ANCIENT GENES AND MODERN MEDICINE [J].
BROWN, P ;
CERVENAKOVA, L ;
GOLDFARB, LG ;
MCCOMBIE, WR ;
RUBENSTEIN, R ;
WILL, RG ;
POCCHIARI, M ;
MARTINEZLAGE, JF ;
SCALICI, C ;
MASULLO, C ;
GRAUPERA, G ;
LIGAN, J ;
GAJDUSEK, DC .
NEUROLOGY, 1994, 44 (02) :291-293
[4]   DIAGNOSIS OF CREUTZFELDT-JAKOB DISEASE BY WESTERN-BLOT IDENTIFICATION OF MARKER PROTEIN IN HUMAN-BRAIN TISSUE [J].
BROWN, P ;
COKERVANN, M ;
POMEROY, K ;
FRANKO, M ;
ASHER, DM ;
GIBBS, CJ ;
GAJDUSEK, DC .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (09) :547-551
[5]   THE NEW BIOLOGY OF SPONGIFORM ENCEPHALOPATHY - INFECTIOUS AMYLOIDOSES WITH A GENETIC TWIST [J].
BROWN, P ;
GOLDFARB, LG ;
GAJDUSEK, DC .
LANCET, 1991, 337 (8748) :1019-1022
[6]   MICE DEVOID OF PRP ARE RESISTANT TO SCRAPIE [J].
BUELER, H ;
AGUZZI, A ;
SAILER, A ;
GREINER, RA ;
AUTENRIED, P ;
AGUET, M ;
WEISSMANN, C .
CELL, 1993, 73 (07) :1339-1347
[7]   NORMAL DEVELOPMENT AND BEHAVIOR OF MICE LACKING THE NEURONAL CELL-SURFACE PRP PROTEIN [J].
BUELER, H ;
FISCHER, M ;
LANG, Y ;
BLUETHMANN, H ;
LIPP, HP ;
DEARMOND, SJ ;
PRUSINER, SB ;
AGUET, M ;
WEISSMANN, C .
NATURE, 1992, 356 (6370) :577-582
[8]   MYOSIN ISOFORM TRANSITIONS IN REGENERATION OF FAST AND SLOW MUSCLES DURING POSTNATAL-DEVELOPMENT OF THE RAT [J].
DALBIS, A ;
COUTEAUX, R ;
JANMOT, C ;
MIRA, JC .
DEVELOPMENTAL BIOLOGY, 1989, 135 (02) :320-325
[9]   DIRECT GENE-TRANSFER IN SKELETAL-MUSCLE - PLASMID DNA-BASED IMMUNIZATION AGAINST THE HEPATITIS-B VIRUS SURFACE-ANTIGEN [J].
DAVIS, HL ;
MICHEL, ML ;
MANCINI, M ;
SCHLEEF, M ;
WHALEN, RG .
VACCINE, 1994, 12 (16) :1503-1509
[10]  
GABIZON R, 1990, BIOCHEM J, V266, P1